Related Experiment Videos
Summary
Butocine, an anti-cancer drug, is rapidly absorbed but poorly excreted by the kidneys. This suggests minimal renal impact, crucial for patients with malignant tumors undergoing treatment.
Area of Science:
- Pharmacology
- Oncology
- Drug Metabolism
Background:
- Malignant tumors present complex physiological challenges.
- Understanding drug pharmacokinetics is vital for effective cancer therapy.
- Butocine is a potential therapeutic agent for cancer treatment.
Purpose of the Study:
- To investigate the pharmacokinetic profile of Butocine.
- To assess the absorption, distribution, metabolism, and excretion (ADME) of Butocine.
- To evaluate the safety and efficacy of Butocine in cancer patients.
Main Methods:
- A single oral dose of 500 mg Butocine was administered to 8 individuals with malignant tumors.
- Serum levels of Butocine were measured at various time points post-administration.
- Urinary excretion and renal clearance of Butocine were determined.
Main Results:
- Butocine demonstrated rapid absorption from the gastrointestinal tract.
- Peak serum concentrations were achieved approximately 45 minutes after dosing.
- Urinary excretion was minimal (2.5% over 15 hours), with very low renal clearance (1.5 ml/min).
Conclusions:
- Butocine exhibits favorable absorption characteristics.
- The drug shows limited renal excretion and clearance, suggesting a low risk of nephrotoxicity.
- These pharmacokinetic properties are promising for the management of malignant tumors.